An in silico approach helped to identify the best experimental design, population, and outcome for future randomized clinical trials

Our approach can help to identify the best experimental design, population, and outcome for future RCTs. This may be particularly useful for drug development in rare diseases, theragnostic approaches, or personalized medicine.